NCT03284502 2023-08-01
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Unknown
Clinical Trials
10 trialsNCT05497336 2022-09-30
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT05155124 2022-09-13
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT05019534 2022-05-19
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
West China Hospital
Phase 1 Unknown
NCT02675946 2022-01-26
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Curegenix Inc.
Phase 1 Unknown
NCT03552406 2021-05-06
Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors
ISU Abxis Co., Ltd.
Phase 1 Unknown
NCT03491709 2019-10-31
A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC
Dragonboat Biopharmaceutical Company Limited
Phase 1 Unknown
NCT03356158 2018-09-17
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1 Unknown
NCT02215720 2016-02-10
TORERO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Unknown
NCT00392470 2011-05-25
Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer
National Cancer Institute (NCI)
Phase 1 Unknown